Loading clinical trials...
Loading clinical trials...
A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis
Conditions
Interventions
Placebo
Bimekizumab
Locations
40
United States
Pa0008 007
San Diego, California, United States
Pa0008 005
Aventura, Florida, United States
Pa0008 003
Hagerstown, Maryland, United States
Pa0008 011
Lansing, Minnesota, United States
Pa0008 025
Lexington, New York, United States
Pa0008 014
Portland, Oregon, United States
Start Date
October 1, 2016
Primary Completion Date
November 1, 2017
Completion Date
July 1, 2018
Last Updated
March 20, 2023
NCT07295509
NCT07286058
NCT06100744
NCT04402086
NCT06888193
NCT07315061
Lead Sponsor
UCB Biopharma S.P.R.L.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions